MultiplAI Health
Cancer is the second leading cause of mortality globally, responsible for 10 million deaths per year.
Cancer diagnosis today is inaccurate, time-consuming and general practitioners may fail to recognise the physical symptoms, which may not present themselves early on. Late diagnosis decreases the chances for successful treatment creating financial and psychological strain for the patient, their families and their doctors.
We want to change this, by making routine and frequent screening for cancer possible for anyone on earth.
We offer a whole blood screening test using RNA sequencing and AI to detect virtually any kind of cancer and other complex diseases.
Rather than searching for signals of a tumor, the test looks for changes in the blood that prove the presence of a specific type of cancer.
This gives MultiplAI the power to:
- Offer a non-invasive whole blood screening test for cancer
- Achieving ~95-99% diagnostic accuracy
- At a fraction of the cost of existing diagnosis methodologies
- Allowing prognosis prediction and evaluation of treatment results
- Administered anywhere you can safely extract a blood sample
Timing is Everything
We are bringing together maturing artificial intelligence,
cost effective sequencing methodology and remote medicine
to detect cancer earlier when it is more treatable.
It’s time to imagine universal remote screening for cancer.
Welcome to the
MultiplAI super-biomarker
With advances in RNA sequencing, bioinformatic processing and deep learning, we now have the power to measure many biomarkers in the blood.
Our patented RNAseq data transformation process makes it possible to represent the incredible complexity of RNA in highly efficient formats ideal for algorithmic analysis.
The Team
Santiago Miriuka (MD, PhD)
Santiago Miriuka (MD, PhD)
Santiago Miriuka (MD, PhD)
Medical Doctor with 20+ years in clinical medicine. Director of a lab of postdocs with 60+ publications working on cutting-edge cellular and molecular biology, and self-taught data scientist and coder.
Carlos Luzzani (PhD)
Santiago Miriuka (MD, PhD)
Santiago Miriuka (MD, PhD)
Molecular biologist and biotech specialist
with experience co- founding a bioprinting startup (WeBio). Investigator at
FLENI-CONICET with 20 peer
reviewed publications.
Mark Paul Ramondt (MBA)
Santiago Miriuka (MD, PhD)
Mark Paul Ramondt (MBA)
Serial (failed) entrepreneur,
angel investor and advisor
to startups with 25+ years of
corporate finance and open
innovation experience.
Advisors
.jpg/:/rs=w:365,h:365,cg:true,m/cr=w:365,h:365/fx-gs)
Nir Ayalon (PhD candidate)
Nir Ayalon (PhD candidate)
Nir Ayalon (PhD candidate)
Serial entrepreneur and computer scientist with contacts in Europe and Israel, and expertise in data science, engineering and data privacy.
Carl Cook (PhD)
Nir Ayalon (PhD candidate)
Nir Ayalon (PhD candidate)
Senior pharmaceutical executive based in Boston with 20+ years of experience in clinical oncology and precision medicine.